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Abstract
Background: Patients with chronic heart failure (CHF) may experience higher mortality of Staphylococcus aureus
bacteremia (SAB) than patients without CHF due to insufficient cardiovascular responses during systemic infection.
We investigated 90-day mortality in SAB patients with and without CHF.
Methods: Using population-based medical databases, we conducted a cohort study of all adult patients with
community-acquired SAB (CA-SAB) in Northern Denmark, 2000-2011. Ninety-day mortality after SAB for patients
with and without CHF was estimated by the Kaplan-Meier method. Based on Cox regression analysis, we computed
hazard ratios as estimates of mortality rate ratios (MRRs) overall and stratified by CHF-related conditions (e.g.,
cardiomyopathy and valvular heart disease), CHF severity (defined by daily dosage of loop-diuretics), and CHF
duration while adjusting for potential confounders.
Results: Among 2638 SAB patients, 390 (14.8 %) had a history of CHF. Ninety-day mortality was 45 % in patients with
CHF and 30 % in patients without CHF, which yielded an adjusted MRR (aMRR) of 1.24 (95 % CI, 1.04-1.48). Compared
to patients without CHF, the excess risk of death was most pronounced among patients with valvular heart disease
(aMRR = 1.73 (95 % CI, 1.26–2.38)), patients with daily loop-diuretic dosages of 81–159 mg/day (aMRR = 1.55 (95 % CI, 1.
11–2.14)) and ≥160 mg/day (aMRR = 1.62 (95 % CI, 1.21–2.18)), and among patients with <3 years of CHF duration
(aMRR = 1.43 (95 % CI, 1.14–1.78)).
Conclusion: CA-SAB patients with CHF experienced increased 90-day mortality compared to patients without CHF.
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Background
Staphylococcus aureus bacteremia (SAB) continues to be
associated with considerable morbidity and a 30-day mor-
tality of 20–40 % in developed countries [1, 2]. Chronic
heart failure (CHF) currently affects more than 23 million
persons worldwide, and hospitalizations and readmissions
for CHF remain a major public health problem [3, 4]. Pa-
tients with CHF may experience higher mortality from
SAB than patients without CHF due to insufficient
cardiovascular responses to severe systemic infection [5].
Further, CHF and SAB share several negative prognostic
factors including male sex, high age, and comorbidity [2].
Still, data on the prognostic impact of CHF in patients
with SAB are limited and inconsistent, and to our know-
ledge no prior prognostic study has addressed CHF as
the main exposure in this clinical setting. Previous stud-
ies have been restricted by a limited number of SAB
patients (N < 400) [6–9], often from referral centers [9],
and CHF has not been defined according to strictly
specified criteria [6–9]. Other limitations include incom-
plete information on comorbid conditions [8, 9], and
lack of follow-up after discharge [8, 9]. Detailed informa-
tion on the prognostic influence of CHF in patients with
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SAB may extend our understanding of the clinical
course of SAB patients and contribute to improved
treatment for patients with CHF. Therefore, we con-
ducted a population-based cohort study to examine the




This cohort study was conducted using routinely re-
corded data from population-based medical registries
in Northern Denmark between 1 January 2000 and 31
December 2011 (catchment population ~ 1.8 million
inhabitants). Tax-supported, unfettered healthcare is
provided for the entire Danish population through a
national health insurance program [10, 11]. Northern
Denmark is served by two University hospitals and a
dwindling number of regional hospitals (22 regional
hospitals in 2000 and 7 regional hospitals in 2011). All
Danish residents are assigned a unique identification
number which allows unambiguous linkage of registry
data at the individual level [10, 11].
Patients with S.aureus bacteremia
Using the databases of the departments of clinical
microbiology within the area, we identified all patients
hospitalized with CA-SAB from 1995 onwards. We in-
cluded patients ≥15 years with ≥1 positive blood cultures
with S.aureus as the sole isolate (information on blood
culture practice and susceptibility testing is provided in
Additional file 1: Identification and susceptibility testing
of S. aureus isolates). Because recurrence of SAB may
affect prognosis [12], we limited the study to patients
with incident SAB, defined as no prior SAB diagnosis
within at least 5 years of the current hospitalization.
CA-SAB was defined as SAB in patients, in whom one
or more positive blood cultures had been obtained within
the first two days of admission. Patients with a first blood
cultured obtained >2 days after admission were excluded,
because we consider these infections to be hospital-
acquired. Patients with CA-SAB and healthcare contacts
recently preceding the current admission were sub-
classified as healthcare-associated SAB (HCA-SAB) if one
or more of the following criteria were met: ≥1 hospital ad-
mission, ≥1 contacts to hospital outpatient surgical clinics
(including minor surgery), or ≥1 contacts to clinics of
hematology, oncology or nephrology, all within a 30-day
window of the current admission.
Data on recent health care contacts were retrieved
using the Danish National Patient Registry (DNPR) [13].
This register holds data on all citizens and permanent
residents admitted to Danish hospitals since 1977 and
all visits to hospital outpatient clinics since 1995. Each
record includes the dates of hospital admission and
discharge, up to 20 discharge diagnoses, and information
on surgical procedures.
Patients with chronic heart failure
Patients diagnosed with CHF at any time before the current
admission were identified from the DNPR [13]. We defined
CHF as a previous hospital discharge diagnosis or out-
patient diagnosis of congestive heart failure, pulmonary
edema with mention of heart failure, left ventricular failure,
unspecified heart failure, cardiomyopathy, or hypertensive
heart disease with congestive heart failure (with or without
hypertensive renal disease or renal failure). CHF patients
were further classified according to presence of CHF-
related conditions: 1) cardiomyopathy (with or without any
of the following diagnoses), 2) valvular heart disease (with
or without any of the other diagnoses except cardiomyop-
athy), 3) previous myocardial infarction (with or without
atrial fibrillation), 4) atrial fibrillation only, and 5) none of
the above concomitant conditions. All diagnostic codes are
provided in Additional file 2: Codes for diagnoses, proce-
dures, medication, and blood tests.
Severity of CHF is not included in the diagnostic codes
in the DNPR. Thus, as a proxy for CHF severity, patients
were categorized according to daily dosage of redeemed
prescriptions of loop-diuretics: non-users (no loop-
diuretics), low dose (≤40 mg/day), medium dose (41–
80 mg/day), high dose (81–159 mg/day), and very high
dose (≥160 mg/day). We computed mean loop-diuretic
dosages by dividing the number of dispensed tablets by a
dispensing time interval of 180 days, as described previ-
ously [14, 15]. Loop-diuretic dosages have been shown
to correlate positively with worsened New York Heart
Association functional class and mortality risk, but not
with glomerular filtration rate in CHF patients [15]. Data
on filled prescriptions were retrieved from the Aarhus
University Prescription Database (AUPD) [16], which
holds data on redeemed prescriptions in the study area
according to the Anatomical Therapeutic Chemical
(ATC) classification system (ATC codes are provided in
Additional file 2: Codes for diagnoses, procedures, medi-
cation, and blood tests). We calculated duration of CHF
as the time elapsed between the first diagnosis of CHF
and the sampling date of the first positive blood culture.
Comorbidity, laboratory test results, and mortality
Data on sex, age, and marital status was retrieved from
the Danish Civil Registration System, which is updated
electronically on a daily basis and keeps track of demo-
graphic data and changes in vital status and migration
for all Danish residents since 1968 [10, 11]. We com-
puted a modified Charlson Comorbidity Index (m-CCI)
using all available diagnoses registered in the DNPR up
to 10 years before the current hospitalization excluding
CHF from the index (the exposure variable of interest).
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The CCI is a validated comorbidity scoring system cov-
ering both the number and severity of 19 major disease
categories [17, 18]. Patients were classified as having a
low (score = 0), intermediate (score = 1–2), or a high
comorbidity level (score >2). We further collated data
on a number of conditions not included in the m-CCI,
counting hypertension, drug- and alcohol-related con-
ditions and dialysis (within 30 days of the current ad-
mission). Using the AUPD [16], we obtained data on
the following filled prescriptions: Any previous use of
antihypertensive treatment, statins (and other lipid low-
ering agents), anticoagulants, and use of immunosup-
pressant drugs, and antibiotics within 30 days of the
SAB-related hospitalization (ATC codes are provided in
Additional file 2: Codes for diagnoses, procedures,
medication, and blood tests). The LABKA Database
(CSC Scandihealth, Denmark) keeps laboratory test
results from patients in Northern Denmark for the en-
tire study period including the exact time of blood sam-
ple collection [19]. Using this database, we obtained
information on white blood count levels on the date
the first positive blood culture was drawn (laboratory
codes are available in Additional file 2: Codes for diag-
noses, procedures, medication, and blood tests). Data
on all-cause mortality was retrieved from the Danish
Civil Registration System [10, 11].
Statistical analyses
All patients were followed from the date the first posi-
tive blood culture was drawn until death, emigration
or 90 days, whichever came first. Patient characteris-
tics (including demographics, comorbidity, and pread-
mission medication use) were tabulated according to
CHF status. We computed the 90-day mortality risk
using the Kaplan-Meier method (1 – survival func-
tion) and graphically displayed 90-day mortality for
patients with and without CHF. Ninety-day mortality
rates for patients with vs. without CHF were compared
using a Cox proportional hazards model estimating
hazard ratios as a measure of mortality rate ratios
(MMRs) with corresponding 95 % confidence intervals
(CIs). CHF exposure was further subcategorized ac-
cording to CHF-related conditions, CHF severity and
CHF duration. To examine whether mortality differed
among subsets of CHF patients, we stratified the ana-
lyses by sex, age category (15–39, 40–59, 60–79, 80+
years), and m-CCI level (“low”, “intermediate”, and
“high”). All MRRs were adjusted for age, sex, condi-
tions included in the m-CCI, hypertension, alcohol
related conditions, marital status (as a marker of
socioeconomic status) and preadmission use of anti-
biotic therapy (within 30 days). The assumption of
proportional hazards in the Cox models was assessed
graphically and found appropriate. We conducted all
statistical analyses using Stata 11.2 for Windows (Stata
Corp, College Station, TX).
Results
Descriptive data
During the study period 2638 patients aged ≥15 years
were hospitalized with incident CA-SAB, of which 390
(14.8 %) had CHF (Table 1). Median age was 77 (inter-
quartile range (IQR), 70–82) and 67 (IQR, 54–78) years
for patients with and without CHF, respectively. There
were slightly more men among patients with CHF com-
pared to patients without CHF (64.9 % vs. 60.6 %).
Forty-eight percent of patients with CHF were classified
as HCA vs. 41.4 % among patients without CHF.
Methicillin-resistant S.aureus (MRSA) was rarely ob-
served (0.5 % of all patients). Patients with CHF had
considerably more hospital-diagnosed comorbidity than
patients without CHF, including diabetes (31.0 % vs.
12.8 %), chronic pulmonary disease (30.8 % vs. 10.8 %),
renal disease (33.3 % vs. 13.6 %), and hypertension
(49.5 % vs. 20.4 %). Compared to patients without CHF,
patients with CHF were more likely to have filled pre-
scriptions for angiotensin-converting-enzyme inhibitors,
beta blockers, acetylsalicylic acid, and statins.
Ninety-day mortality
Ninety-day cumulative mortality was 44.6 % in patients
with CHF and 30.4 % in patients without CHF, respect-
ively (Table 2 and Fig. 1). This yielded an unadjusted
MRR of 1.60 (95 % CI, 1.36–1.89), and an adjusted MRR
of 1.24 (1.04–1.48). Compared to 30.4 % among patients
without CHF, 90-day mortality was 30.8 % among pa-
tients with concomitant cardiomyopathy (aMRR = 1.04
(95 % CI, 0.63–1.72)), 60 % among patients with a his-
tory of valve disease (aMRR = 1.73 (95 % CI, 1.26–2.38)),
41.2 % among patients with previous myocardial infarc-
tion (aMRR = 1.17 (95 % CI, 0.83–1.65)), and 41.0 %
among CHF patients with none of the above concomi-
tant conditions (aMRR = 1.12 (0.83–1.50)).
Compared to patients without CHF, an increased risk of
death within 90 days was observed among patients with
dosages of 81–159 mg/day (aMRR = 1.55 (95%CI, 1.11–
2.14)) and ≥160 mg/day (1.62 (95 % CI, 1.21–2.18)),
whereas no association was noted among patients with
daily intakes of loop-diuretics ≤80 mg/day (Table 2).
Ninety-day mortality was 50 % among patients with CHF
of <3 years as compared to 30.4 % among patients with no
CHF, corresponding to an aMRR of 1.43 (95 % CI, 1.14–
1.78). Longer duration of CHF did not appear to be associ-
ated with a poor outcome: Thus, compared with patients
with no history of CHF, the aMRR was 1.01 (95 % CI,
0.71–1.46) for ≥3- < 6 years of CHF, 1.22 (95 % CI, 0.84-
1.78) for ≥6- < 10 years of CHF and 0.97 (95 % CI, 0.61–
1.54) for ≥10 years of CHF history. We observed no
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consistent pattern or major differences in 90-day mortality
according to sex, age, or m-CCI level (Table 3).
Discussion
In this large cohort study of 2638 patients with incident
SAB, we observed a 24 % increase in 90-day all-cause
mortality associated with CHF. Compared to patients
without CHF, the excess risk of death within 90 days was
most pronounced among CHF patients with concomi-
tant valvular disease, patients with CHF of less than
3 years duration, and patients with a daily loop-diuretic
dosage above 80 mg/day.
Our results are in line with the limited existing know-
ledge on the impact of CHF on mortality in SAB pa-
tients [6–9]. In a Norwegian cohort study of 374
patients with SAB, Paulsen et al. [6] observed an age-
and sex-adjusted odds ratio (OR) of 2.4 (95 % CI, 1.21–
4.80) for 30-day mortality comparing patients with and
without CHF. In a Swiss cohort study [9] including 308
SAB patients from a single referral center, the authors
observed an unadjusted OR of 2.4 (95 % CI, 1.0–5.6) of
death within 90 days associated with CHF. A Columbian
cohort study [7] examining risk factors of 90-day mortal-
ity in 267 cancer patients with SAB reported a hazard
ratio of 10.6 (95 % CI, 1.8–63.7) comparing patients with
and without CHF. Finally, a Taiwanese cohort study of
227 patients with persistent MRSA-SAB [8], found an
30-day mortality OR of 2.85 (95 % CI, 1.44–5.65) for pa-
tients with CHF compared to patients without. However,
several issues should be taken into account when inter-
preting the results of these previous studies: Small and
selected study populations [7, 8], limited numbers of
patients with CHF (n < 70) [6–9], and insufficient adjust-
ment for concomitant comorbid conditions [8, 9], could
partly explain the findings. Moreover, in contrast to our
study, none of the previous studies investigated the im-
pact of CHF on mortality according to CHF-related con-
ditions, CHF severity or duration of CHF [6–9].
Table 1 Characteristics of 2638 patients hospitalized with






Numbers (%) 390 (14.8) 2248 (85.2)
Age, median (IQR) 76.6 (66.9–82.2) 67.4 (54.4–78.3)
15–39 years 12 (3.1) 221 (9.8)
40–59 years 48 (12.3) 557 (24.8)
60–79 years 194 (49.7) 988 (44.0)
≥ 80 years 136 (34.9) 482 (21.4)
Sex
Men 253 (64.9) 1363 (60.6)
Women 137 (35.1) 885 (39.4)
S.aureus bacteremia
Community-acquired 203 (52.1) 1320 (58.7)
Healthcare-associated 187 (48.0) 928 (41.3)
MRSA 3 (0.8) 10 (0.4)
Marital status
Married 203 (52.1) 1067 (47.5)
Divorced or widowed 152 (39.0) 734 (32.7)
Never married 35 (9.0) 447 (19.9)
Selected comorbid
conditions
Diabetes mellitus 121 (31.0) 287 (12.8)
Peripheral vascular disease 99 (25.4) 229 (10.2)
Cerebrovascular disease 76 (19.5) 239 (10.6)
Chronic pulmonary disease 120 (30.8) 243 (10.8)
Moderate to severe renal
disease
130 (33.3) 306 (13.6)
Hypertension 193 (49.5) 458 (20.4)
Conditions related to
alcohol abuse
26 (6.7) 209 (9.3)
Conditions related to drug
abuse
4 (1.0) 69 (3.1)
Dialysis within 30 days of
admission
61 (15.6) 203 (9.0)
Modified Charlson
Comorbidity Index
Low (0) 42 (10.8) 720 (32.0)
Intermediate (1–2) 129 (33.1) 826 (36.7)




3 (0.8) 25 (1.1)
Systemic antibiotic
therapya
82 (21.0) 454 (20.2)
ACE inhibitorsb 298 (76.4) 788 (35.1)
Beta blockersb 271 (69.5) 764 (34.0)
Acetylsalicylic acidb 301 (71.2) 820 (36.5)
Table 1 Characteristics of 2638 patients hospitalized with
incident Staphylococcus aureus bacteremia in Northern Denmark,
2000-2011 (Continued)
Statinsb 174 (44.6) 451 (20.1)
Clinical biochemistry
White blood count (109/L)c
< 3.5 11 (2.8) 100 (4.5)
3.5–10 52 (13.3) 440 (19.6)
> 10 262 (67.2) 1292 (57.5)
Unknown 65 (16.7) 416 (18.5)
IQR interquartile range, MRSA methicillin resistant Staphylococcus aureus, ACE
inhibitors angiotensin-converting-enzyme inhibitors
aAny use within 30 days of the current admission. bAny previous use prior to
the current admission
cMeasured on the date the first positive blood culture was drawn
Smit et al. BMC Infectious Diseases  (2016) 16:227 Page 4 of 8
Table 2 Ninety-day mortality in incident Staphylococcus aureus bacteremia patients with versus without chronic heart failure (CHF)
Number Mortality % (95 % CI) Crude MRR (95 % CI) Adjusteda MRR (95 % CI)
CHF
Absent 2248 30.4 (28.6–32.4) 1.00 (ref.) 1.00 (ref.)
Present 390 44.6 (39.8–49.7) 1.60 (1.36–1.89) 1.24 (1.04–1.48)
CHF-related conditions
CHF absent 2248 30.4 (28.6–32.4) 1.0 (ref.) 1.0 (ref.)
Cardiomyopathy 52 30.8 (20.1–45.2) 0.99 (0.60–1.62) 1.04 (0.63–1.72)
Valvular heart disease 70 60.0 (48.8–71.4) 2.44 (1.79–3.34) 1.73 (1.26–2.38)
Myocardial infarction 85 41.2 (31.6–52.4) 1.45 (1.04–2.05) 1.17 (0.83–1.65)
Atrial fibrillation 66 50.0 (38.7–62.5) 1.81 (1.27–2.57) 1.21 (0.85–1.73)
None of the above 117 41.0 (32.7–50.5) 1.46 (1.09–1.95) 1.12 (0.83–1.50)
CHF severityb
CHF absent 2248 30.4 (28.6–32.4) 1.00 (ref.) 1.00 (ref.)
Non-users 99 32.2 (24.1–42.5) 1.08 (0.76–1.54) 0.99 (0.69–1.42)
Low dose (≤40 mg/day) 39 38.5 (25.3–55.5) 1.30 (0.78–2.16) 0.83 (0.50–1.40)
Medium dose (41–80 mg/day) 82 42.7 (32.8–54.1) 1.52 (1.08–2.14) 1.13 (0.80–1.59)
High dose (81–159 mg/day) 75 53.3 (42.6–64.9) 2.05 (1.49–2.83) 1.55 (1.11–2.14)
Very high dose (≥160 mg/day) 95 54.7 (45.1–64.9) 2.10 (1.59–2.79) 1.62 (1.21–2.18)
Duration of CHF
CHF absent 2248 30.4 (28.6–32.4) 1.00 (ref.) 1.00 (ref.)
< 3 years 188 50.0 (43.1–57.3) 1.83 (1.48–2.27) 1.43 (1.14–1.78)
≥ 3- < 6 years 81 39.5 (29.8–51.0) 1.39 (0.98–1.99) 1.01 (0.71–1.46)
≥ 6- < 10 years 69 42.0 (31.4–54.5) 1.52 (1.05–2.21) 1.22 (0.84–1.78)
≥ 10 years 52 36.5 (25.1–51.1) 1.25 (0.79–1.97) 0.97 (0.61–1.54)
CI confidence interval, MRR mortality rate ratio
aAdjusted for age, sex, conditions included in the modified Charlson Comorbidity Index (excluding the condition in question), hypertension, alcohol related
conditions, marital status, and antibiotic treatment within 30 days of admission
bDefined by daily loop-diuretic dosage
Fig. 1 Cumulative mortality risk among incident Staphylococcus aureus bacteremia patients with and without chronic heart failure
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Several mechanisms may underlie our observations.
Myocardial dysfunction is a well-known complication of
sepsis [20, 21]. Cardiac dysfunction in patients with sepsis
is characterized by ventricular dilatation, decreased ejection
fraction, and blunted ability to increase cardiac output des-
pite elevated catecholamine levels [20]. Patients with CHF
may be especially susceptible to these mechanisms, which
could partly explain our observed difference in mortality
among patients with versus without this underlying condi-
tion. Still, patients with CHF were older, more frequently
men, and had more comorbidity registered than those with-
out CHF, all of which are important prognostic factors in
patients with SAB [2]. Adjusting for these factors in our
model attenuated the association between CHF and mortal-
ity suggesting that a considerable part of the high mortality
associated with SAB is conveyed by the combined burden
of age, sex and comorbidity. In our study, the increased 90-
day mortality associated with CHF was most pronounced
among CHF patients with valvular heart disease and among
patients with short duration of CHF. CHF patients with
concomitant valvular heart disease may in particular be at
high risk of pulmonary edema and circulatory collapse sec-
ondary to sepsis. However, valvular heart disease represents
a major risk factor for infective endocarditis [22], which
may add to the poor prognosis of these patients. The mech-
anisms underlying the increased risk of death among pa-
tients with short duration of CHF remain unclear and may
most likely be multifactorial. It is possible, however, that pa-
tients with shorter duration of CHF differ from patients
with long CHF duration with regards to CHF management
and clinical stability which may influence the outcome from
CA-SAB.
Our study has several strengths including its size,
population-based design and adjustment for relevant
confounders facilitated by our access to medical databases
ensuring a complete prescription and hospitalization his-
tory. All data was collected prospectively and independently
of the study hypothesis, thus reducing the risk of selection
and information biases, and follow-up was virtually
complete. However, some important limitations should be
addressed in the interpretation of our results. Identification
of patients with CHF from medical databases may be ham-
pered by inaccurate coding, which would bias our results
towards unity. Yet, two recent Danish validation studies re-
ported positive predictive values for chronic heart failure in
the DNPR of 81 % [23] and 100 % [19], respectively. Physi-
cians may be more likely to admit patients with CHF on
suspicion of infection compared to patients without CHF.
Such surveillance bias would induce an underestimation of
the relative risk associated with SAB. However, white blood
counts of patients with and without CHF were comparable,
and the proportions of patients who had received antibi-
otics prior to the current admission were almost similar. In
addition, we observed no substantial differences in the pro-
portions of patients classified as HCA-SAB among the two
groups. This argues against, but does not preclude notable
bias associated with the triage and treatment of patients
with CHF in our study. On the other hand, the clinical
management of patients with CA-SAB was not standard-
ized across hospitals, which might have influenced our
Table 3 Ninety-day mortality comparing incident community-acquired Staphylococcus aureus bacteremia in patients with and with
chronic heart failure (CHF), stratified by sex, age, and modified Charlson Comorbidity Index level
Patients without CHF Patients with CHF
Mortality % (95 % CI) Mortality % (95 % CI) Adjusteda MRR
Overall 30.4 (28.6–32.4) 44.6 (39.8–49.7) 1.2 (1.0–1.5)
Sex
Male 27.8 (25.5–30.3) 38.7 (33.1–45.0) 1.2 (1.0–1.5)
Female 34.5 (31.4–37.7) 55.5 (47.4–63.9) 1.3 (1.0–1.7)
Age
15–39 years 5.4 (3.1–9.4) n/ab n/ab
40–59 years 18.5 (15.5–22.0) 27.1 (16.7–42.0) 1.5 (0.8–2.7)
60–79 years 31.6 (28.8–34.6) 44.9 (38.2–52.1) 1.6 (1.2–2.0)
80+ years 53.3 (48.9–57.8) 54.4 (46.3–62.9) 1.1 (0.8–1.4)
Modified Charlson Comorbidity Index level
Low (0) 23.9 (20.9–27.2) 42.9 (30.0–59.1) 1.2 (0.7–1.9)
Intermediate (1–2) 30.4 (27.4–33.7) 43.4 (35.4–52.4) 1.2 (0.9–1.6)
High (3+) 37.2 (33.7–40.9) 45.7 (39.3–52.5) 1.3 (1.0–1.7)
Reference group: patients without CHF
CI confidence interval, MRR mortality rate ratio
aAdjusted for age, sex, conditions included in the modified Charlson Comorbidity Index (excluding CHF), hypertension, alcohol related conditions, marital status,
and antibiotic treatment within 30 days of admission
bNot applicable due to absence of events
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results. Furthermore, we lacked data on infective foci in-
cluding venous catheters and other vascular access devices,
which have been associated with SAB prognosis in several
prior studies [1, 2].
We used loop-diuretic dosage as a proxy for CHF se-
verity, since we did not have access to data on ejection
fraction or New York Heart Association Functional
Class among patients with CHF. If some patients used
loop-diuretics for other reasons than CHF (e.g., con-
comitant renal failure) this may have led us to underesti-
mate any differences between less severe and severe
CHF, although we do not expect this to alter our overall
conclusions. Finally, the medical databases did not con-
tain data on smoking and obesity, still these potential
confounders may be partly accounted for by adjustment
for lifestyle-associated comorbidities included in our
statistical models.
Due to the low prevalence of MRSA in our study area
[24], these data and results may not be directly applic-
able to settings with higher MRSA prevalence. Still, our
results may most likely be applicable to other healthcare
systems with equal unfettered access to medical care
and prescription medication including CHF drugs.
Conclusion
In summary, patients with CA-SAB and CHF experi-
enced higher 90-day mortality than patients without
CHF, which was most apparent among CHF patients
with valvular heart disease, patients with a short history
of CHF, and patients with high daily dosages of loop-
diuretics. SAB patients with CHF may benefit from the
collaborated care of infectious diseases specialists and
cardiologists ensuring increased adherence to evidence-
based guidelines, optimized post-discharge follow-up
and possibly improved clinical outcomes.
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